NanoVibronix, Inc. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
NAOV Nasdaq 3850 www.nanovibronix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NanoVibronix, Inc.

NanoVibronix Regains Nasdaq Compliance - Apr 11th, 2025 12:00 pm
NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia - Apr 1st, 2025 12:00 pm
Why Nanovibronix Inc. (NAOV) Surged On Thursday? - Mar 21st, 2025 10:36 am
Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal - Mar 14th, 2025 12:00 pm
NanoVibronix Announces Reverse Stock Split - Mar 12th, 2025 12:00 pm
NanoVibronix, Inc. Announces Acquisition of ENvue Medical Holdings, Corp. - Feb 14th, 2025 2:43 pm
NanoVibronix Advances Development of PainShield and UroShield with Completion of NextGen Prototypes - Jan 7th, 2025 1:00 pm
Transforming catheter care: NanoVibronix completes successful UroShield US trial - Jan 7th, 2025 10:53 am
NanoVibronix “achieves goals” of US trial pilot phase with UroShield - Jan 6th, 2025 4:16 pm
NanoVibronix Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan - Jan 6th, 2025 1:00 pm
NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement - Dec 11th, 2024 1:00 pm
NanoVibronix Third Quarter 2024 Earnings: US$0.36 loss per share (vs US$0.42 loss in 3Q 2023) - Nov 17th, 2024 2:08 pm
NanoVibronix Provides Business Update - Nov 12th, 2024 1:00 pm
NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany - Oct 9th, 2024 12:30 pm
NanoVibronix Signs Letter of Intent with Potential New Distributor - Sep 23rd, 2024 12:30 pm
NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders - Aug 21st, 2024 12:30 pm
NanoVibronix Second Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.65 loss in 2Q 2023) - Aug 17th, 2024 12:54 pm
NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan - May 22nd, 2024 12:30 pm
NanoVibronix Issues Letter to Stockholders - May 16th, 2024 12:30 pm
NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield - May 14th, 2024 12:30 pm